suPAR - a future risk marker in bacteremia

Journal of Internal Medicine

Volumn 270, Issue 1, 2011, Pages 29-31

  Eugen Olsen, Jesper ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; C REACTIVE PROTEIN; LIPID; PROCALCITONIN; UROKINASE RECEPTOR;

AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL INFECTION; BODY MASS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CELL ADHESION; CELL MIGRATION; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOW GRADE INFLAMMATION; MORTALITY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT; SIGNAL TRANSDUCTION;

BACTEREMIA; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 79959358673     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02372.x     Document Type: Editorial

References (19)

1. Wittenhagen P, Kronborg G, Weis N et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004; 10: 409-15.
2. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39: 23-31.
3. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6: 686-92.
4. Ostrowski SR, Ullum H, Goka BQ et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005; 191: 1331-41.
5. Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, Koksal I. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol 2010; 50: 209-11.
6. Rabna P, Andersen A, Wejse C et al. High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Int Health 2009; 14: 986-94.
7. Kofoed K, Andersen O, Kronborg G et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007; 11: R38.
8. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008; 27: 375-83.
9. Ostrowski SR, Plomgaard P, Fischer CP et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol 2005; 61: 197-206.
10. Roldan AL, Cubellis MV, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
11. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-33.
12. Dano K, Behrendt N, Hoyer-Hansen G et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-81.
13. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.
14. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157-72.
15. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217-24.
16. Eugen-Olsen J, Andersen O, Linneberg A et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296-308.
17. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-5.
18. Huttunen R, Syrjänen J, Vuento R et al. Plasma level of soluble urokinase-type plasminogen activator receptor (suPAR) as a predictor of disease severity and case fatality in patients with bacteremia: a prospective cohort study. J Intern Med 2011 (Epub ahead of print).
19. Langkilde AA, Hansen TW, Ladelund S et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 2011 (Epub ahead of print).